Legend Biotech (LEGN)

Executive Summary

Legend Biotech (NASDAQ: LEGN) is a global cell therapy leader focused on oncology, with its approved CAR-T product, ciltacabtagene autoleucel (cilta-cel), co-developed with Janssen. Cilta-cel is approved in the U.S., EU, and China for relapsed/refractory multiple myeloma, and is poised for label expansion into earlier treatment lines. The company's pipeline includes 36 candidates addressing hematologic malignancies and solid tumors, with early-phase trials exploring CAR-T and NK cells for autoimmune diseases. Supported by a robust manufacturing strategy and strong commercialization partner, Legend is positioned to capture significant market share in the multi-billion-dollar CAR-T space. Near-term catalysts include regulatory decisions and clinical data readouts that could drive valuation growth, though competition from other BCMA-directed therapies remains a key risk.

Upcoming Catalysts (preview)

• Q2 2027Cilta-cel label expansion to earlier lines of multiple myeloma (e.g., frontline or first relapse)60% success
• Q3 2026Regulatory approval decision for cilta-cel in Japan80% success
• Q4 2026Phase 1 data readout for LCAR-AIO T cells in autoimmune indications (e.g., multiple sclerosis)40% success